Eastbourne Proposes Amylin Directors, Backs Icahn
Tuesday, February 3, 2009 : PermalinkBloomberg – Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it “lost confidence” in leadership of the maker of the Byetta diabetes drug.
Eastbourne, which owns 12.5 percent of San Diego-based Amylin, said in a letter to management yesterday that the company’s board needs to be “significantly strengthened” after the stock fell almost 80 percent since Oct. 5, 2007. In November, Eastbourne said it was talking with Amylin about options including “a possible acquisition by a third party.”
Tags: acquisition, amylin pharmaceuticals inc, byetta, capital-management-llc, carl-icahn, confidence, diabetes, diabetes drug, investor, leadership, oct 5, s board, san diego, slate, stock, third-party
trackback from your site.